NEW YORK (GenomeWeb) – Bio-Techne today announced a strategic agreement with China's Lisen Imprinting Diagnostics Wuxi in the field of precision medicine.
Specifically, the partnership, Minneapolis-based Bio-Techne said, will accelerate the development of molecular diagnostics in the Chinese market. Financial and other terms of the agreement were not disclosed.
Bio-Techne provides consumables and instruments for the life science and molecular diagnostic markets. It's nucleotide RNAscope Assay product line is an RNA in situ hybridization platform for molecular pathology. Meanwhile, Lisen develops diagnostic assays and services for oncology, and according to Bio-Techne, the technology can detect changes in the early stages of tumor progression.
"It is believed that this collaboration with Bio-Techne will give full play to the technological advantages of both parties and accelerate the development and market promotion of new diagnostic products," Lisen Imprinting Diagnostics Wuxi CEO Ning Zhou said in a statement.